Aluminium in Allergies and Allergen immunotherapy

World Allergy Organization Journal

Erika Jensen-Jarolim¹ 

[1] Comparative Medicine, Messerli Research Institute, The University of Vet. Medicine Vienna, the Medical University Vienna, and the University Vienna, Währinger G. 18-20, Vienna, 1090, Austria

关键词: Th2;    Allergen immunotherapy;    Adjuvant;    Aluminium;    Allergen;   

Others  :  1137514
DOI  :  10.1186/s40413-015-0060-5

 received in 2014-10-24, accepted in 2015-02-06,  发布年份 2015

【 摘 要 】

Aluminium is a hot topic in the current debate. Exposure occurs due to environmental, dietary and intentional exposure to aluminium, such as in vaccines where it was introduced in 1926. In spite of the fact that it is a typical Th2 adjuvant, aluminium redirects the immune response in systemic allergen immunotherapy (SIT) upon prolonged immunization. SIT in the US, and SLIT in general, are at present non-adjuvanted therapies, but in Europe aluminium is used as adjuvant in most SIT preparations. It enhances the safety of SIT by local deposition of the allergen. Undesired properties of aluminium adjuvants comprise acute and chronic inflammation at the injection site, its Th2 immune stimulatory capacity, its accumulation besides biodistribution in the body. The adjuvant and safety profile of aluminium adjuvants in allergy vaccines are discussed, as well as the need for putting modern delivery systems and adjuvants on the fast track.

【 授权许可】

   
2015 Jensen-Jarolim; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Glenny AT, Pope CG, Waddington H, Wallace U: Immunological notes XVLL.-XXIV. J Pathol Bacteriol 1926, 29:31-40. doi:10.1002/Path.1700290106
• [2]Bousfield G: Clinical trials of diphtheria toxoid aluminium-phosphate-precipitated; to determine optional aluminium-phosphate content. Lancet 1947, 1:286-8.
• [3]Mc Comb J, Trafton MZ: Immune responses and reactions to diphtheria and tetanus toxoids, with pertussis vaccine, aluminum phosphate precipitated. N Engl J Med 1950, 243:442-4. doi:10.1056/NEJM195009212431204
• [4]Baylor NW, Egan W, Richman P: Aluminum salts in vaccines–US perspective. Vaccine 2002, 20(Suppl 3):S18-23.
• [5]Lindblad EB: Aluminium compounds for use in vaccines. Immunol Cell Biol 2004, 82:497-505. doi:10.1111/j.0818-9641.2004.01286.x
• [6]Hussels F. [Eight to twelve month follow-up of the results of rapid treatment of syphilis with PAM, procaine penicillin G in oil with aluminum monostearate]. Therapie der Gegenwart. 1950;89:332–6.
• [7]Bohls SW, Cook EB, Potter RT: Oral and parenteral use of aluminum penicillin mixtures in the treatment of gonorrhea. J Vener Dis Inf 1946, 27:69-74.
• [8]Hirsh HL, Kurland W: The treatment of various infections with single doses of 300,000 units of procaine penicillin in oil plus aluminum monostearate. Am Pract Dig Treat 1950, 1:923-5.
• [9]McIntosh JF, Sutherland CG: The Use of Colloidal Aluminium Hydroxide in the Treatment of Peptic Ulcer. Can Med Assoc J 1940, 42:140-5.
• [10]Rossien AX, Stanton A, Feuerstein SS: An evaluation of the antacid activity of a “special” aluminum hydroxide mixture. Rev Gastroenterol 1951, 18:535-9.
• [11]Friedman MH: Aluminum hydroxide gel for erosions in patients with bowel fistulas. JAMA 1946, 131:520-2.
• [12]Clark BB, Adams WL: The effect of gastric antacids on gastric secretion as observed in the Cope pouch dog; sodium bicarbonate, aluminum hydroxide gel, calcium carbonate, magnesium oxide, and sodium citrate. Gastroenterology 1947, 9:284-92.
• [13]Akdis M, Akdis CA: Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov 2009, 8:645-60. doi:10.1038/nrd2653
• [14]Soyka MB, Holzmann D, Akdis CA: Regulatory cells in allergen-specific immunotherapy. Immunotherapy 2012, 4:389-96. doi:10.2217/imt.12.10
• [15]Holgate ST, Polosa R: Treatment strategies for allergy and asthma. Nat Rev Immunol 2008, 8:218-30. doi:10.1038/nri2262
• [16]Jarolim E, Poulsen LK, Stadler BM, Mosbech H, Oesterballe O, Kraft D, et al.: A long-term follow-up study of hyposensitization with immunoblotting. J Allergy Clin Immunol 1990, 85:996-1004.
• [17]Freeman J: Further observations on the treatment of Hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911, 2:814-7.
• [18]Noon L: Prophylactic inoculation against hay fever. Lancet 1911, 1:1572-3.
• [19]Zoss A, Koch C, Hirose R: Alum-ragweed precipitate: preparation and clinical investigation; preliminary. J Allergy 1937, 8:329.
• [20]Naterman HL: Pollen tannate suspended in peanut oil with aluminum monostearate in the treatment of hay fever. J Allergy 1951, 22:175-82.
• [21]Holzman RS, Norman PS: The effect of alum concentration on the repository and adjuvant properties of alum-precipitated antigens. J Allergy 1966, 38:65-73.
• [22]Moingeon P: Adjuvants for allergy vaccines. Hum Vaccines Immunother 2012, 8:1492-8. doi:10.4161/hv.21688
• [23]Levine BB, Vaz NM: Effect of combinations of inbred strain, antigen, and antigen dose on immune responsiveness and reagin production in the mouse. A potential mouse model for immune aspects of human atopic allergy. Int Arch Allergy Appl Immunol 1970, 39:156-71.
• [24]Revoltella R, Ovary Z: Preferential production of rabbit reaginic antibodies. Int Arch Allergy Appl Immunol 1969, 36:282-9.
• [25]Revoltella R, Ovary Z: Reaginic antibody production in different mouse strains. Immunology 1969, 17:45-54.
• [26]Black L: The adjuvant activity of saponin and aluminium hydroxide for promoting reagins. J Immunol Methods 1977, 15:193-5.
• [27]Lehrer SB, Vaughn JH, Tan EM: Enhancement of reaginic and hemagglutinating antibody production by an extract of Bordetella pertussis containing histamine sensitizing factor. J Immunol 1976, 116:178-83.
• [28]Pauwels R, Van der Straeten M, Platteau B, Bazin H: The non-specific enhancement of allergy. I. In vivo effects of Bordetella pertussis vaccine on IgE synthesis. Allergy 1983, 38:239-46.
• [29]Marsh DG, Lichtenstein LM, Norman PS: Induction of IgE-mediated immediate hypersensitivity to group I rye grass pollen allergen and allergoids in non-allergic man. Immunology 1972, 22:1013-28.
• [30]Kepron W, James JM, Kirk B, Sehon AH, Tse KS: A canine model for reaginic hypersensitivity and allergic bronchoconstriction. J Allergy Clin Immunol 1977, 59:64-9.
• [31]Black L: Allergy in cattle after foot-and-mouth disease vaccination. Vet Rec 1977, 100:195-8.
• [32]Itaya T, Tomioka H, Kumagai A, Tada T: Suppression of IgE antibody formation in mice with nonspecific stimulation. Int Arch Allergy Appl Immunol 1980, 62:389-96.
• [33]Flarend RE, Hem SL, White JL, Elmore D, Suckow MA, Rudy AC, et al.: A. In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Vaccine 1997, 15:1314-8.
• [34]Brunner R, Jensen-Jarolim E, Pali-Scholl I: The ABC of clinical and experimental adjuvants–a brief overview. Immunol Lett 2010, 128:29-35. doi:10.4161/hv.21688
• [35]Moingeon P, Mascarell L: Novel routes for allergen immunotherapy: safety, efficacy and mode of action. Immunotherapy 2012, 4(2):201-212. doi:10.2217/Imt.11.171
• [36]Ekramoddoullah AK, Kisil FT, Sehon AH: Suppression of the IgE antibody response in mice to kentucky blue grass pollen allergens. Int Arch Allergy Appl Immunol 1977, 55:247-54.
• [37]Wachholz PA, Soni NK, Till SJ, Durham SR: Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003, 112:915-22. doi:10.1016/S0091
• [38]Hantusch B, Scholl I, Harwanegg C, Krieger S, Becker WM, Spitzauer S, et al.: Affinity determinations of purified IgE and IgG antibodies against the major pollen allergens Phl p 5a and Bet v 1a: discrepancy between IgE and IgG binding strength. Immunol Lett 2005, 97:81-9. doi:10.1016/j.imlet.2004.10.002
• [39]Hogenesch H: Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol 2012, 3:406. doi:10.3389/fimmu.2012.00406
• [40]Marrack P, McKee AS, Munks MW: Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009, 9:287-93. doi:10.1038/nri2510
• [41]McKee AS, Munks MW, MacLeod MK, Fleenor CJ, Van Rooijen N, Kappler JW, et al.: Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009, 183:4403-14. doi:10.4049/jimmunol.0900164
• [42]Kuroda E, Coban C, Ishii KJ: Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects. Int Rev Immunol 2013, 32:209-20. doi:10.3109/08830185.2013.773326
• [43]Pollock KG, Conacher M, Wei XQ, Alexander J, Brewer JM: Interleukin-18 plays a role in both the alum-induced T helper 2 response and the T helper 1 response induced by alum-adsorbed interleukin-12. Immunology 2003, 108:137-43.
• [44]Exley C, Siesjo P, Eriksson H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol. 2010;31:103–9. doi:10.1016/J.It.2009.12.009
• [45]Sun H, Pollock KG, Brewer JM: Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 2003, 21:849-55.
• [46]Manzano-Szalai K, Thell K, Willensdorfer A, Weghofer M, Pfanzagl B, Singer J, et al. Adeno-associated virus-like particles as new carriers for B-cell vaccines: testing immunogenicity and safety in BALB/c mice. Viral Immunol. 2014. doi:10.1089/vim.2014.0059.
• [47]Hebert J, Small P: Comparison of alum-precipitated aqueous extracts and modified ragweed tyrosine adsorbate vaccine in the treatment of ragweed hay fever. Ann Allergy 1988, 60:226-30.
• [48]Boye NP, Salo OP, Hyldebrandt N, Wihl JA, Bevan A, Harris RI, et al.: Immunotherapy of tree pollen allergy with a modified alginate conjugated birch pollen extract compared to an aluminium adsorbed extract. Allergy 1990, 45:241-8.
• [49]Scholl I, Boltz-Nitulescu G, Jensen-Jarolim E: Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy. J Control Release 2005, 104:1-27. doi:10.1016/j.jconrel.2004.12.020
• [50]Pali-Scholl I, Szollosi H, Starkl P, Scheicher B, Stremnitzer C, Hofmeister A, et al. Protamine nanoparticles with CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response in BALB/c mice. Eur J Pharm Biopharm. 2013;85:656–64. doi:10.1016/J.Ejpb.2013.03.003
• [51]Roth-Walter F, Scholl I, Untersmayr E, Fuchs R, Boltz-Nitulescu G, Weissenbock A, et al.: M cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen immunotherapy. J Allergy Clin Immunol 2004, 114:1362-8. doi:10.1016/j.jaci.2004.08.010
• [52]Kool M, Fierens K, Lambrecht BN: Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol 2012, 61:927-34. doi:10.1099/jmm. 0.038943-0
• [53]Exley C: Aluminium adjuvants and adverse events in sub-cutaneous allergy immunotherapy. Allergy, Asthma, and Clinical Immunology : official journal of the Canadian Society of Allergy and. Clin Immunol 2014, 10:4. doi:10.1186/1710-1492-10-4
• [54]Garcia-Patos V, Pujol RM, Alomar A, Cistero A, Curell R, Fernandez-Figueras MT, et al.: Persistent subcutaneous nodules in patients hyposensitized with aluminum-containing allergen extracts. Arch Dermatol 1995, 131:1421-4.
• [55]Heidary N, Cohen DE: Hypersensitivity reactions to vaccine components. Dermatitis : contact, atopic, occupational, drug 2005, 16:115-20.
• [56]Osterballe O: Side effects during immunotherapy with purified grass pollen extracts. Allergy 1982, 37:553-62.
• [57]Netterlid E, Hindsen M, Siemund I, Bjork J, Werner S, Jacobsson H, et al.: Does allergen-specific immunotherapy induce contact allergy to aluminium? Acta Derm Venereol 2013, 93:50-6. doi:10.2340/00015555-1409
• [58]Exley C: Human exposure to aluminium. Environ Sci Processes Impacts 2013, 15:1807-16. doi:10.1039/c3em00374d
• [59]Martyn CN, Barker DJ, Osmond C, Harris EC, Edwardson JA, Lacey RF: Geographical relation between Alzheimer’s disease and aluminum in drinking water. Lancet 1989, 1:59-62.
• [60]World Health Organizaion. Aluminium. Geneva, WHO International Programme on Chemical Safety (Environmental Health Criteria 194). 1997.
• [61]European Food Safety Authority, EFSA. Technical report: Dietary exposure to aluminium-containing food additives. http://www.efsa.europa.eu/en/supporting/pub/411e.htm. March 2013.;Parma, Italy:Supporting Publications 2013:EN-411.
• [62]Roth LE, Dunlap JR, Stacey G: Localizations of Aluminum in Soybean Bacteroids and Seeds. Appl Environ Microb 1987, 53:2548-53.
• [63]Food and Drug Administration, Dept. of Health and Human Services. 21. Food and Drugs. Biologics: General Biological Product Standards. 21CFR61015. 1 April 2014; 7:http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=610.15.
• [64]Vaccine-Education-Center. Do vaccines contain aluminum? Reviewed by Offit, PA. http://vec.chop.edu/service/vaccine-education-center/vaccine-safety/vaccine-ingredients/aluminum.html. March 2014.
• [65]Willhite CC, Karyakina NA, Yokel RA, Yenugadhati N, Wisniewski TM, Arnold IM, et al.: Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts. Crit Rev Toxicol 2014, 44(Suppl 4):1-80. doi:10.3109/10408444.2014.934439
• [66]Banasik A, Lankoff A, Piskulak A, Adamowska K, Lisowska H, Wojcik A: Aluminum-induced micronuclei and apoptosis in human peripheral-blood lymphocytes treated during different phases of the cell cycle. Environ Toxicol 2005, 20:402-6. doi:10.1002/tox.20125
• [67]Tomljenovic L, Shaw CA: Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. Lupus 2012, 21:223-30. doi:10.1177/0961203311430221
• [68]Schwarz MJ: Cytokines, neurophysiology, neuropsychology, and psychiatric symptoms. Dialogues Clin Neurosci 2003, 5:139-53.
• [69]Khan Z, Combadiere C, Authier FJ, Itier V, Lux F, Exley C, et al.: Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. BMC Med 2013, 11:99. doi:10.1186/1741-7015-11-99 BioMed Central Full Text
• [70]De Sole P, Rossi C, Chiarpotto M, Ciasca G, Bocca B, Alimonti A, et al.: Possible relationship between Al/ferritin complex and Alzheimer’s disease. Clin Biochem 2013, 46:89-93. doi:10.1016/j.clinbiochem.2012.10.023
• [71]Mold M, Eriksson H, Siesjo P, Darabi A, Shardlow E, Exley C: Unequivocal identification of intracellular aluminium adjuvant in a monocytic THP-1 cell line. Sci Rep 2014, 4:6287. doi:10.1038/srep06287
• [72]Brunner R, Wallmann J, Szalai K, Karagiannis P, Altmeppen H, Riemer AB, et al.: Aluminium per se and in the anti-acid drug sucralfate promotes sensitization via the oral route. Allergy 2009, 64:890-7.
• [73]Brunner R, Wallmann J, Szalai K, Karagiannis P, Kopp T, Scheiner O, et al.: The impact of aluminium in acid-suppressing drugs on the immune response of BALB/c mice. Clin Exp Allergy 2007, 37:1566-73. doi:10.1111/j.1365-2222.2007.02813.x
• [74]Rosenblum H, Shoenfeld Y, Amital H: The common immunogenic etiology of chronic fatigue syndrome: from infections to vaccines via adjuvants to the ASIA syndrome. Infect Dis Clin North Am 2011, 25:851-63. doi:10.1016/j.idc.2011.07.012
• [75]Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y: Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun 2013, 47:1-16. doi:10.1016/j.jaut.2013.10.004
• [76]Soriano A, Nesher G, Shoenfeld Y. Predicting post-vaccination autoimmunity: Who might be at risk? Pharmacol Res. Epub 2014/10/04. doi:10.1016/j.phrs.2014.08.002.
• [77]Commission of the French Parliament. 2/7 Colloque de L’OPECST sur les effets secondaires d’adjuvants vaccinaux. YouTube. 22 May 2014; https://www.youtube.com/watch?v=zmpKMGGiJpg&feature=youtu.be.
• [78]Greßler S, Fries R. Aluminium. Toxikologie und gesundheitliche Aspekte bei körpernahen Anwendungen. Publisher: Austrian Ministry of Health, (editor Herzog, U). http://www.bmg.gv.at/cms/home/attachments/3/9/6/CH1146/CMS1402477436830/aluminium_studie_2014.pdf. June 2014.